RU2009106089A - Композиции, содержащие полипептид эндогенного ретровируса человека, и способы их применения - Google Patents

Композиции, содержащие полипептид эндогенного ретровируса человека, и способы их применения Download PDF

Info

Publication number
RU2009106089A
RU2009106089A RU2009106089/15A RU2009106089A RU2009106089A RU 2009106089 A RU2009106089 A RU 2009106089A RU 2009106089/15 A RU2009106089/15 A RU 2009106089/15A RU 2009106089 A RU2009106089 A RU 2009106089A RU 2009106089 A RU2009106089 A RU 2009106089A
Authority
RU
Russia
Prior art keywords
immunogenic composition
composition according
herv
polypeptide
individual
Prior art date
Application number
RU2009106089/15A
Other languages
English (en)
Russian (ru)
Inventor
Марио ОСТРОВСКИ (CA)
Марио ОСТРОВСКИ
Р. Брэдли ДЖОНС (CA)
Р. Брэдли ДЖОНС
Сет РАКОФФ-НАХОУМ (US)
Сет РАКОФФ-НАХОУМ
Дуглас НИКСОН (US)
Дуглас НИКСОН
Кейт ГАРРИСОН (US)
Кейт ГАРРИСОН
Дункан МЕЙКЛЕДЖОН (US)
Дункан МЕЙКЛЕДЖОН
Эшиш АГРАУОЛ (US)
Эшиш АГРАУОЛ
Джэк ЛЕНЦ (US)
Джэк ЛЕНЦ
Фредерик М. ХЕХТ (US)
Фредерик М. ХЕХТ
Original Assignee
Те Риджентс Оф Те Юниверсити Оф Калифорния (Us)
Те Риджентс Оф Те Юниверсити Оф Калифорния
ТЕ Дж. ДЭВИД ГЛЭДСТОУН ИНСТИТЬЮТС (US)
ТЕ Дж. ДЭВИД ГЛЭДСТОУН ИНСТИТЬЮТС
Альберт Эйнштейн Коллидж Оф Медсин (Us)
Альберт Эйнштейн Коллидж Оф Медсин
Марио ОСТРОВСКИ (CA)
Марио ОСТРОВСКИ
ДЖОУНЗ Р Брэдли (CA)
ДЖОУНЗ Р Брэдли
Сет РАКОФФ-НАХОУМ (US)
Сет РАКОФФ-НАХОУМ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Те Риджентс Оф Те Юниверсити Оф Калифорния (Us), Те Риджентс Оф Те Юниверсити Оф Калифорния, ТЕ Дж. ДЭВИД ГЛЭДСТОУН ИНСТИТЬЮТС (US), ТЕ Дж. ДЭВИД ГЛЭДСТОУН ИНСТИТЬЮТС, Альберт Эйнштейн Коллидж Оф Медсин (Us), Альберт Эйнштейн Коллидж Оф Медсин, Марио ОСТРОВСКИ (CA), Марио ОСТРОВСКИ, ДЖОУНЗ Р Брэдли (CA), ДЖОУНЗ Р Брэдли, Сет РАКОФФ-НАХОУМ (US), Сет РАКОФФ-НАХОУМ filed Critical Те Риджентс Оф Те Юниверсити Оф Калифорния (Us)
Publication of RU2009106089A publication Critical patent/RU2009106089A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
RU2009106089/15A 2006-07-21 2007-07-19 Композиции, содержащие полипептид эндогенного ретровируса человека, и способы их применения RU2009106089A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83246506P 2006-07-21 2006-07-21
US60/832,465 2006-07-21

Publications (1)

Publication Number Publication Date
RU2009106089A true RU2009106089A (ru) 2010-08-27

Family

ID=38957380

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2009106089/15A RU2009106089A (ru) 2006-07-21 2007-07-19 Композиции, содержащие полипептид эндогенного ретровируса человека, и способы их применения

Country Status (15)

Country Link
US (2) US20080171061A1 (enExample)
EP (1) EP2046380A4 (enExample)
JP (1) JP2009544614A (enExample)
KR (1) KR20090060410A (enExample)
CN (1) CN101557823A (enExample)
AU (1) AU2007275693A1 (enExample)
BR (1) BRPI0714714A2 (enExample)
CA (1) CA2658393A1 (enExample)
IL (1) IL196516A0 (enExample)
MX (1) MX2009000659A (enExample)
NO (1) NO20090818L (enExample)
RU (1) RU2009106089A (enExample)
SG (1) SG173997A1 (enExample)
WO (1) WO2008011120A2 (enExample)
ZA (1) ZA200900379B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE045482T2 (hu) 2005-06-27 2019-12-30 Glaxosmithkline Biologicals Sa Immunogén készítmény
US20090297530A1 (en) * 2006-05-22 2009-12-03 Feng Wang-Johanning Herv-k antigens, antibodies, and methods
EP2340851A4 (en) * 2008-09-18 2012-09-26 Univ Keio DIAGNOSTIC METHOD AND THERAPEUTIC METHOD FOR CANCER
WO2010053772A2 (en) 2008-10-29 2010-05-14 The Regents Of The University Of California Disease-associated antigens and methods of use thereof
EP2519539A4 (en) * 2009-12-28 2013-11-13 Ligocyte Pharmaceuticals Inc METHODS FOR STABILIZING VIRUS-LIKE PARTICULATE SOLUTIONS BASED ON INFLUENZA-INFLUENZA-VIRUSED VIRUSES
US20120321637A1 (en) * 2011-06-20 2012-12-20 The Board Of Regents Of The University Of Texas System Combination cancer therapy with herv inhibition
IL330095A (en) 2012-01-26 2026-08-01 Vanda Pharmaceuticals Inc Tesimalta for use in the treatment of asynchronous circadian rhythm of cortisol
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
US20160145348A1 (en) 2013-03-14 2016-05-26 Fred Hutchinson Cancer Research Center Compositions and methods to modify cells for therapeutic objectives
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
EP4166161B1 (en) 2016-04-14 2026-03-04 Fred Hutchinson Cancer Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
JP7046016B2 (ja) 2016-06-30 2022-04-01 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ Ｈｅｒｖ－ｅ反応性ｔ細胞受容体および使用方法
WO2018037042A1 (en) * 2016-08-23 2018-03-01 Aimvion A/S Novel immunostimulating peptides
WO2018129270A1 (en) 2017-01-05 2018-07-12 Fred Hutchinson Cancer Research Center Systems and methods to improve vaccine efficacy
EP3606550A2 (en) * 2017-04-03 2020-02-12 Neon Therapeutics, Inc. Protein antigens and uses thereof
US11351247B2 (en) 2017-09-01 2022-06-07 Inprother Aps Vaccine for use in the prophylaxis and/or treatment of a disease
TW201930340A (zh) 2017-12-18 2019-08-01 美商尼恩醫療公司 新抗原及其用途
WO2019143948A1 (en) 2018-01-18 2019-07-25 Fred Hutchinson Cancer Research Center Altering inflammatory states of immune cells in vivo by modulating cellular activation states
SG11202012653XA (en) 2018-06-19 2021-01-28 Biontech Us Inc Neoantigens and uses thereof
WO2020049169A1 (en) * 2018-09-06 2020-03-12 Centre Léon-Bérard Herv-k-derived antigens as shared tumor antigens for anti-cancer vaccine
US20220259617A1 (en) 2019-06-13 2022-08-18 The General Hospital Corporation Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells
BR112023001272A2 (pt) 2020-07-24 2023-04-04 Massachusetts Gen Hospital Partículas semelhantes a vírus aprimoradas e métodos de uso das mesmas para entrega às células
WO2024108001A2 (en) * 2022-11-16 2024-05-23 The General Hospital Corporation Minimal human-derived virus-like particles and methods of use thereof for delivery of biomolecules
US20260035415A1 (en) * 2024-08-01 2026-02-05 Twilight Bioscience, Inc. Herv-k (hml-2) env analog fusion proteins for antigen specific immunotherapy and methods of use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030092145A1 (en) * 2000-08-24 2003-05-15 Vic Jira Viral vaccine composition, process, and methods of use
US20030162263A1 (en) * 2001-09-06 2003-08-28 Marc Dupuis Peptides derived from the superantigen (SAg) ENV protein of HERV-K18 and their use in obtaining SAG-inhibitory antibodies and in vaccination against SAG
AT411262B (de) * 2001-09-27 2003-11-25 Wolff Klaus Dr Humanes endogenes retrovirus
JP4822490B2 (ja) * 2001-12-07 2011-11-24 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 腫瘍形成形質転換に関連する内因性レトロウイルスポリペプチド
US20040096457A1 (en) * 2001-12-11 2004-05-20 Huber Brigitte T Treatment and prevention of ebv infection and ebv-associated disorders
EP1338606A1 (en) * 2002-02-22 2003-08-27 Magnus Von Knebel Doeberitz Nucleic Acid encoding an HERV-H polypeptide for diagnosing colorectal cancer
US20130108653A1 (en) * 2009-12-22 2013-05-02 Shervin Bahrami Bivalent molecules for hiv entry inhibition
US20120321637A1 (en) * 2011-06-20 2012-12-20 The Board Of Regents Of The University Of Texas System Combination cancer therapy with herv inhibition

Also Published As

Publication number Publication date
WO2008011120A2 (en) 2008-01-24
US20080171061A1 (en) 2008-07-17
CA2658393A1 (en) 2008-01-24
EP2046380A4 (en) 2013-05-01
BRPI0714714A2 (pt) 2013-04-09
CN101557823A (zh) 2009-10-14
IL196516A0 (en) 2011-08-01
AU2007275693A1 (en) 2008-01-24
SG173997A1 (en) 2011-09-29
ZA200900379B (en) 2010-08-25
KR20090060410A (ko) 2009-06-12
JP2009544614A (ja) 2009-12-17
US20130323279A1 (en) 2013-12-05
NO20090818L (no) 2009-04-17
MX2009000659A (es) 2009-06-08
EP2046380A2 (en) 2009-04-15
WO2008011120A3 (en) 2008-11-06

Similar Documents

Publication Publication Date Title
JP2009544614A5 (enExample)
Paliard et al. Priming of strong, broad, and long-lived HIV type 1 p55gag-specific CD8+ cytotoxic T cells after administration of a virus-like particle vaccine in rhesus macaques
Tomiyama et al. Evidence of presentation of multiple HIV-1 cytotoxic T lymphocyte epitopes by HLA-B* 3501 molecules that are associated with the accelerated progression of AIDS
TW202200199A (zh) 冠狀病毒疫苗及使用方法
RU2721274C2 (ru) Иммуногены для вакцинации против вич
KR102569204B1 (ko) B형 간염 바이러스 감염에 대한 치료 백신접종을 위한 합성 롱 펩티드(slp)
US20050271676A1 (en) Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions
EP1225907A1 (en) Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions
CN107011426A (zh) 针对癌症的靶向细胞周期蛋白a1的t细胞免疫疗法
EA030741B1 (ru) Адъювантное соединение
RU2011138160A (ru) Пептиды foxmi и вакцины, содержащие их
NO314588B1 (no) HIV-peptider, antigener, vaksinesammensetning, immunoassay- testsett og en fremgangsmåte for å påvise antistoffer indusert av HIV
JP2014207910A (ja) 多価ワクチン
EP3466980A2 (en) Improved human herpesvirus immunotherapy
RU2009101191A (ru) Sparc-производные антигенные пептиды отторжения опухоли и лекарственные средства, содержащие их
WO2014004385A2 (en) Anti-cancer vaccines
CN115715199A (zh) 冠状病毒疫苗
Suhrbier Polytope vaccines for the codelivery of multiple CD8T-cell epitopes
Ohno et al. Synthetic peptides coupled to the surface of liposomes effectively induce SARS coronavirus-specific cytotoxic T lymphocytes and viral clearance in HLA-A* 0201 transgenic mice
JP2013523084A5 (enExample)
RU2014121502A (ru) Пептиды торк и содержащие их вакцины
US11690906B2 (en) Compositions and methods to treat aids
RU2014109137A (ru) Пептиды mphosph1 и вакцины, включающие их
RU2011140168A (ru) Пептиды vangl1 и содержащие их вакцины
RU2011150283A (ru) Пептиды ттк и вакцины, их содержащие

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20120130